Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
Vijairam SelvarajMohammad Saud KhanChirag BavishiKwame Dapaah-AfriyieArkadiy FinnAmos LalEleftherios MylonakisPublished in: Lung (2021)
Tocilizumab therapy improves outcomes of mortality and need for mechanical ventilation, in hospitalized patients with COVID-19 infection compared with standard therapy or placebo. Our findings suggest the efficacy of tocilizumab therapy in hospitalized COVID-19 patients and strengthen the concept that tocilizumab is a promising therapeutic intervention to improve mortality and morbidity in COVID-19 patients.
Keyphrases
- rheumatoid arthritis
- mechanical ventilation
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- sars cov
- randomized controlled trial
- intensive care unit
- systematic review
- acute respiratory distress syndrome
- risk factors
- clinical trial
- type diabetes
- disease activity
- metabolic syndrome
- cardiovascular disease
- coronary artery disease
- systemic lupus erythematosus
- extracorporeal membrane oxygenation
- bone marrow
- open label
- chemotherapy induced